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Supplementary Table 
Supplementary Table 1: pSIRM approach was performed using CaCO2-control, CaCO2-BRAFV600E 
and CaCO2-KRASG12V cells (in minimum n=3). Mean of quantities (pmol/L 000 000 cells), 13C-glucose 
incorporation (LI [%]) and normalized labeled quantities (NLQ [pmol/L 000 000 cells]) of metabolites 
(product of quantities and incorporation). Cells were cultivated and labeled for 5 min with physiological 
amounts of glucose (1.0 g/L). Ala: Alanine, Cit: Citric acid, Fum: Fumaric acid, Lac: Lactic acid, Mal: 
Malic acid, Pyr: Pyruvic acid, Ser: Serine, Suc: Succinic acid. 
 
Cell line CaCO2-control CaCO2-BRAFV600E CaCO2-KRASG12V 
quantities Ser 18935 15076 71435 
 
Pyr 2805 969 2568 
 
Lac 41227 45932 32545 
 
Ala 4097 865 688 
 
Cit 2493 3110 4167 
 
Suc 1641 1766 3635 
 
Fum 763 901 1565 
 
Mal 1843 1189 4354 
LI Ser 0.3 0.7 0.4 
 
Pyr 20.9 24.3 26.4 
 
Lac 16.7 18.5 10.7 
 
Ala 3.3 6.3 5.4 
 
Cit 10.8 18.5 11.0 
 
Suc 9.1 9.2 9.3 
 
Fum 1.7 1.9 0.5 
 
Mal 13.6 14.2 13.2 
NLQ Ser 46 120 95 
 
Pyr 527 241 864 
 
Lac 6716 8538 3745 
 
Ala 98 60 35 
 
Cit 343 650 448 
 
Suc 160 190 377 
 
Fum 14 19 8 
 
Mal 262 180 629 
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Supplementary Figures 
Supplement Figure 1: A) Cells were cultivated in the presence of Doxycycline and indicated glucose 
concentrations for 16 d. B) CaCO2-control, CaCO2-BRAFV600E and CaCO2-KRASG12V cells were 
cultivated in medium containing 1.0 g/L glucose and measured with LC-MS (shot gun proteomics). 
Shown are log2 fold changes (fc) to CaCO2-control cells for proteins associated with epithelial to 
mesenchymal transition, migration and actin remodeling. Significant regulations (p<0.05 unpaired two-
tailed t Test) comparing CaCO2-control and CaCO2-BRAFV600E or CaCO2-control and CaCO2-
KRASG12V cells were indicated with asterisks or crosses, respectively. C) CaCO2-control, CaCO2-
BRAFV600E and CaCO2-KRASG12V cells cultivated in medium containing physiological (1.0 g/L) 
glucose were stained with periodic acid-Schiff (PAS) and alcian blue (AB) to verify neutral and acidic 
Mucin expression in vacuoles, respectively. D) MUC5AC expression was analyzed using ELISA assay. 
Cells were cultivated in physiological (1.0 g/L) glucose. Data were quantified and shown as log2 fold 
changes (fc). B, C, E) Shown are standard deviation of n=3 replicates. p<0.05 was indicated with asterisk 
(unpaired two-tailed t Test). 
 
Supplement Figure 2: A, B) Flow cytometry profiles of CaCO2-control, CaCO2-BRAFV600E, CaCO2-
KRASG12V, HT29 and SW480 cells cultivated with indicated glucose amounts stained for cleaved 
Caspase 3. Shown are percent (%) of apoptotic cells. Shown are standard of n=2 replicates. p<0.05 was 
indicated with asterisk (unpaired two-tailed t Test)). C, D) CaCO2-control, CaCO2-BRAFV600E, CaCO2-
KRASG12V, HT29 and SW480 cells grown in physiological (1.0 g/L) glucose concentrations were treated 
with 10 µM Rapamycin (+), 10 µM OSI027 (+) or DMSO (-) for 24 h and analyzed with antibody 
against phosphorylated 4eBP1 (Thr70). Vinculin served as loading control. Samples for each cell line 
were loaded on separate gels. E, H) Phosphorylation of S6-kinase after treatment with 10 µM 
Rapamycin (+), 10 µM OSI027 (+) or DMSO (-) and AKT after treatment with 1 µM (+) MK2206 or 
DMSO (-) for 24 h was analyzed with ELISA bead-based phosphoproteomics technology (BioPlex). 
Shown are log2 fold changes (fc) to DMSO control (per cell line). F, G) CaCO2-control, CaCO2-
BRAFV600E, CaCO2-KRASG12V, HT29 and SW480 cells grown in physiological glucose concentrations 
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were treated with 1 µM MK2206 (+) or DMSO (-) for 24 h. Shown are viable cells compared to DMSO. 
Shown are standard deviation of n=3 replicates. p<0.05 was indicated with asterisk (unpaired two-tailed 
t Test). I, J) CaCO2-control, CaCO2-BRAFV600E, CaCO2-KRASG12V, HT29 and SW480 cells grown in 
physiological (1.0 g/L) glucose concentrations were treated with 1 µM MK2206  (+) or DMSO (-) for 
24 h and analyzed with antibody against phosphorylated 4eBP1 (Thr70). Vinculin served as loading 
control. Samples for each cell line were loaded on separate gels. G) BRAF was immunoprecipitated and 
the immuncomplexes were blotted using antibodies against BRAF and RAPTOR (different plots). IP 
and lysates were loaded on different gels. Vinculin served as loading control. 
 
Supplement Figure 3: A) Hierarchical clustering of relative protein quantities (z-score) were shown 
for CaCO2-control, CaCO2-BRAFV600E and CaCO2-KRASG12V cells cultivated in physiological (1.0 
g/L) glucose. Proteins associated to central carbon metabolism were indicated per cluster. Enrichment 
analysis was done using gene ontology biological process terms. B-D) CaCO2-control, CaCO2-
BRAFV600E and CaCO2-KRASG12V cells were exposed to 1.0 g/L (B, C) or 2.5 g/L (D) of 13C-glucose 
for 5 min, harvested and measured with GC-MS. The ratio (log 2 fold changes, fc) of B) CaCO2-
BRAFV600E to CaCO2-control, C) CaCO2-KRASG12V to CaCO2-control or D) CaCO2-KRASG12V to 
CaCO2-BRAFV600E for labeled (metabolites) quantities are shown. E) CaCO2-control, CaCO2-
BRAFV600E and CaCO2-KRASG12V cells were exposed to 13C-glucose (physiological and intermediate 
amounts) for 5 min, harvested and measured with GC-MS. Extracellular lactic acid quantities were 
depicted. Shown are standard deviation of n=3 replicates. p<0.05 was indicated with asterisk (unpaired 
two-tailed t Test). 
 
Supplement Figure 4: A) CaCO2-control, CaCO2-BRAFV600E and CaCO2-KRASG12V cells were 
cultivated with indicated glucose concentrations and analyzed with quantitative real time PCR for MCT1 
and MCT4 expression. PGK1 served as loading control. Relative mRNA expression to CaCO2-control 
cultured with 1.0 g/L glucose was shown. B, C) CaCO2-control, CaCO2-BRAFV600E, CaCO2-
KRASG12V, HT29 and SW480 cells cultivated in medium containing 1.0 g/L or 2.5 g/L glucose 
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concentrations and treated with 0.1 µM SR13800 for 24 h were analyzed using quantitative real time 
PCR for MCT1 and MCT4 expression. PGK1 served as loading control. Relative mRNA expression to 
DMSO was shown. glc: glucose. A-C) Shown are standard deviation of (in minimum) n=3 replicates. 
p<0.05 was indicated with asterisk (unpaired two-tailed t Test). 
 
Supplement Figure 5: A) CaCO2-control, CaCO2-BRAFV600E and CaCO2-KRASG12V cells were subcu-
taneously injected into the right flank of mice in the presence of Doxycycline (Dox) every 2 d by 
intraperitoneal injection. Mean of tumor volume is shown for n=3 mice per group up to 14 d. B) CaCO2-
KRASG12V were subcutaneously injected into the right flank of mice receiving 200 µL PBS or BrPy (8 
mg/kg) in the presence of Doxycycline treatment every 2 days (starting from day 8) by intraperitoneal 
injection. Hematoxylin eosin staining (H&E) staining was performed from paraffin embedded sections. 
 
Supplementary Information for blots: 
Full length blot to Figure 3A 
Full length blot to Figure 3B 
Full length blot to Figure 6D 
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